TIM-4 Identifies IFN-γ–Expressing Proinflammatory B Effector 1 Cells That Promote Tumor and Allograft Rejection

B cells give rise to polarized subsets, including B effector 1 (Be1) cells and regulatory B cells, which can promote or inhibit immune responses through expression of IFN-γ and IL-10, respectively. Such subsets likely explain why B cell depletion can either ameliorate or exacerbate inflammatory diseases; however, these cells remain poorly understood because of the absence of specific markers. Although T cell Ig and mucin domain-containing molecule (TIM)-1 broadly identifies IL-10 + regulatory B cells, no similar markers for Be1 cells have been described. We now show that TIM-4 is expressed by a subset of B cells distinct from those expressing TIM-1. Although TIM-1 + B cells are enriched for IL-10, TIM-4 + B cells are enriched for IFN-γ. TIM-1 + B cells enhanced the growth of B16-F10 melanoma. In contrast, TIM-4 + B cells decreased B16-F10 metastasis and s.c. tumor growth, and this was IFN-γ dependent. TIM-1 + B cells prolonged islet allograft survival in B-deficient mice, whereas TIM-4 + B cells accelerated rejection in an IFN-γ-dependent manner. Moreover, TIM-4 + B cells promoted proinflammatory Th differentiation in vivo, increasing IFN-γ while decreasing IL-4, IL-10, and Foxp3 expression by CD4 + T cells-effects that are opposite from those of TIM-1 + B cells. Importantly, a monoclonal anti-TIM-4 Ab promoted allograft tolerance, and this was dependent on B cell expression of TIM-4. Anti-TIM-4 downregulated T-bet and IFN-γ expression by TIM-4 + B cells and indirectly increased IL-10 expression by TIM-1 + B cells. Thus, TIM-4 + B cells are enriched for IFN-γ-producing proinflammatory Be1 cells that enhance immune responsiveness and can be specifically targeted with anti-TIM-4.